臨床検査58巻3号

2014年03月発行

今月の特集2 知っておくべき睡眠呼吸障害のあれこれ

睡眠呼吸障害と併存疾患のバイオマーカー

著者： 藤本圭作¹

所属機関： ¹信州大学　医学部保健学科生体情報検査学講座

ページ範囲：P.368 - P.371

●閉塞型睡眠時無呼吸症候群（OSAS）では心臓・脳血管障害，高血圧症，耐糖能障害，脂質代謝異常といった併存症を高率に引き起こし，生命予後に重大な影響を与える．

●OSASによる睡眠障害ストレス，間欠的低酸素は，高感度C反応性蛋白（CRP）および炎症性サイトカインの産生増加，酸化ストレスの増強，血管内皮障害，凝固能亢進，交感神経活動の亢進，インスリン抵抗性をきたし，心臓・脳血管障害，糖尿病，脂質代謝異常の危険因子となる．

●睡眠呼吸障害を診断するバイマーカーはいまだみつかっていないが，併存症の発症にかかわるさまざまなバイオマーカーの測定は，併存症発症のリスクや持続的陽圧呼吸療法（CPAP）の治療効果の判定に有用と考えられる．

参考文献

1）Tasali E, Ip MS：Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc　5：207-217，2008

2）Kent BD, Ryan S, McNicholas WT：Obstructive sleep apnea and inflammation: relationship to cardiovascular co-morbidity. Respir Physiol Neurobiol　178：475-481，2011

3）Agatsuma T, Fujimoto K, Komatsu Y, et al：A novel device (SD-101) with high accuracy for screening sleep apnoea-hypopnoea syndrome. Respirology　14：1143-1150，2009

4）Montesi SB, Bajwa EK, Malhotra A：Biomarkers of sleep apnea. Chest　142：239-245，2012

5）Ryan S, McNicholas WT：Inflammatory cardiovascular risk markers in obstructive sleep apnoea syndrome. Cardiovasc Hematol Agents Med Chem　7：76-81，2009

6）Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al：Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation　105：2462-2464，2002

7）Muraki I, Tanigawa T, Yamagishi K, et al：Nocturnal intermittent hypoxia and C reactive protein among middle-aged community residents: a cross-sectional survey. Thorax　65：523-527，2010

8）Steiropoulos P, Tsara V, Nena E, et al：Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest　132：843-851，2007

9）Drager LF, Bortolotto LA, Lorenzi MC, et al：Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med　172：613-618，2005

10）Minoguchi K, Yokoe T, Tazaki T, et al：Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med　172：625-630，2005

11）Ohga E, Nagase T, Tomita T, et al：Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol (1985)　87：10-14，1999

12）Chin K, Nakamura T, Shimizu K, et al：Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med　109：562-567，2000

13）Lavie L：Obstructive sleep apnoea syndrome--an oxidative stress disorder. Sleep Med Rev　7：35-51，2003

14）Carpagnano GE, Kharitonov SA, Resta O, et al：Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest　122：1162-1167，2002

15）Alonso-Fernández A, García-Río F, Arias MA, et al：Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax　64：581-586，2009

16）Durán-Cantolla J, Aizpuru F, Montserrat JM, et al：Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. BMJ　341：c5991，2010

17）Pépin JL, Tamisier R, Barone-Rochette G, et al：Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med　182：954-960，2010

18）Cho JG, Witting PK, Verma M, et al：Tissue vibration induces carotid artery endothelial dysfunction: a mechanism linking snoring and carotid atherosclerosis? Sleep　34：751-757，2011

19）Ip MS, Tse HF, Lam B, et al：Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med　169：348-353，2004

20）Ueda S, Yamagishi S, Kaida Y, et al：Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology (Carlton)　12：582-590，2007

21）Ohike Y, Kozaki K, Iijima K, et al：Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure--possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J　69：221-226，2005

22）Bokinsky G, Miller M, Ault K, et al：Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest　108：625-630，1995

23）von Känel R, Loredo JS, Ancoli-Israel S, et al：Association between sleep apnea severity and blood coagulability: Treatment effects of nasal continuous positive airway pressure. Sleep Breath　10：139-146，2006

24）Ip MS, Lam B, Ng MM, et al：Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med　165：670-676，2002

25）Harsch IA, Schahin SP, Radespiel-Tröger M, et al：Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med　169：156-162，2004

26）Papanas N, Steiropoulos P, Nena E, et al：HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men. Vasc Health Risk Manag　5：751-756，2009

27）Cintra F, Tufik S, D’Almeida V, et al：Cysteine: a potential biomarker for obstructive sleep apnea. Chest　139：246-252，2011

28）Gozal D, Jortani S, Snow AB, et al：Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in pediatric obstructive sleep apnea. Am J Respir Crit Care Med　180：1253-1261，2009